EUVIMEDEUVIMED entdecken
Crossref

Treatment of psoriatic arthritis and therapeutic perspectives: an Update

Jihad Moulay Berkchi

Société Marocaine de Rhumatologie · 01.01.2023

DOI: 10.24398/a.476.2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Société Marocaine de Rhumatologie, erschienen am 01.01.2023. Verfasst von Jihad Moulay Berkchi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis is a very heterogeneous chronic inflammatory arthritis. Currently, with the progress of knowledge in physiopathology, we have a rich therapeutic arsenal. In addition to so-called “conventional synthetic” disease-modifying treatments, in recent years we have seen the development of several biological “targeted” therapies as well as biosimilars. These different treatments are proposed according to the clinical presentation and the presence of comorbidities. At the same time, symptomatic treatments, namely nonsteroidal anti-inflammatory drugs (NSAIDs), oral but also injectable corticosteroids, are also part of the treatments for psoriatic arthritis, even if their role is secondary, they make it possible to temporarily manage a flare-up of the disease.

Schlagwörter

psoriatic arthritisdisease-modifying antirheumatic drugsbiologic therapybiosimilarsnonsteroidal anti-inflammatory drugscorticosteroidsdisease flarestreatment selectioncomorbidities

Zitieren

APA

Berkchi, J. M. (2023). Treatment of psoriatic arthritis and therapeutic perspectives: an Update. Société Marocaine de Rhumatologie. https://doi.org/10.24398/a.476.2023

Vancouver

Berkchi JM. Treatment of psoriatic arthritis and therapeutic perspectives: an Update. Société Marocaine de Rhumatologie. 2023. doi:10.24398/a.476.2023

BibTeX
@article{Berkchi2023,
  author = {Berkchi, Jihad Moulay},
  title = {Treatment of psoriatic arthritis and therapeutic perspectives: an Update},
  journal = {Société Marocaine de Rhumatologie},
  year = {2023},
  doi = {10.24398/a.476.2023}
}
Kostenlos starten →